References
Januschowski K, Feltgen N, Pielen A et al (2016) Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-016-3471-2
Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 124:193–198
Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 148:266–271
Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Benefict of bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591
Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86
Călugăru D, Călugăru M (2016) Central retinal vein occlusion: modifying current treatment protocols. Eye (Lond) 30:1395–1396
Călugăru D, Călugăru M (2016) Intravitreal aflibercept for macula oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab and ranibizumab. Eye (Lond) 30:766
Călugăru D, Călugăru M (2016) Retinal vein occlusion, from basics to the latest treatment. Retina 36:e112–e113
Călugăru D, Călugăru M (2015) Therapies for macular edema associated with central retinal vein occlusions. Ophthalmology 122:e65–e66
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C. and M.C.) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.
The authors have full control of the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Rights and permissions
About this article
Cite this article
Călugăru, D., Călugăru, M. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 255, 1043–1044 (2017). https://doi.org/10.1007/s00417-017-3617-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-017-3617-x